Cancer Therapeutics Maker, Boundless Bio, Drops 11% after $100M IPO

By
Amadeus Von Ziegler
1 min read
⚠️ Heads up: this article is from our "experimental era" — a beautiful mess of enthusiasm ✨, caffeine ☕, and user-submitted chaos 🤹. We kept it because it’s part of our journey 🛤️ (and hey, everyone has awkward teenage years 😅).

Shares of Boundless Bio Inc., a cancer therapeutics maker backed by Bayer AG, fell nearly 11% after raising $100 million in a US initial public offering. The San Diego-based company’s shares declined to $14.25 each on Thursday, below their IPO price of $16 — the midpoint of a $15 to $17 marketed range.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings

We use cookies on our website to enable certain functions, to provide more relevant information to you and to optimize your experience on our website. Further information can be found in our Privacy Policy and our Terms of Service . Mandatory information can be found in the legal notice